

Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer

Katerina Politi^{1,2} and Thomas J. Lynch¹

Most lung adenocarcinoma-associated EGF receptor (*EGFR*) mutations confer sensitivity to specific *EGFR* tyrosine kinase inhibitors. The finding that exon 19 insertion mutations are also sensitive to this class of drugs suggests that testing for these mutations should be done and that these patients will benefit from treatment with tyrosine kinase inhibitors. *Clin Cancer Res*; 18(6); 1490–2. ©2012 AACR.

In this issue of *Clinical Cancer Research*, He and colleagues (1) show that a rare class of EGF receptor (*EGFR*) mutations, namely exon 19 insertions, is associated with sensitivity to tyrosine kinase inhibitors (TKI), providing a rationale for the testing of these mutations in lung adenocarcinoma patients.

Ninety percent of all lung adenocarcinoma-associated *EGFR* mutations are in frame deletions in exon 19 or a point mutation in exon 21 (L858R) and fall within the exons that encode the tyrosine kinase domain of the receptor (2–4). These mutations confer transforming ability to the receptor and lead to its constitutive activation (5). *EGFR* mutations are most frequently found in tumors from never-smokers and East Asians. Retrospective and prospective studies have established that 70% of tumors harboring these mutations respond to treatment with the *EGFR* TKIs gefitinib or erlotinib (6).

The progression-free survival and response rate of patients with *EGFR*-mutant tumors treated with an *EGFR* TKI is superior to standard chemotherapeutic regimens (7, 8). Despite the promising results, the development of acquired resistance to these therapies is almost inevitable. Drug resistance emerges most frequently as a result of a secondary mutation in exon 20 of *EGFR* that leads to substitution of a methionine for a threonine at position 790 (T790M; ref. 9). The T790M mutation is almost always observed in conjunction with a sensitivity-conferring mutation and is only rarely found in tumors prior to treatment with an *EGFR* TKI.

The remaining 10% of *EGFR* mutations found in lung adenocarcinomas include insertions in exon 20 (about 4% of *EGFR* mutations) and point mutations that modify

codons G719 (to A, C, or S; 3%) and L861 (to Q; 2%; refs. 10, 11). Point mutations that alter these latter residues are also transforming and confer sensitivity to *EGFR* TKIs. In contrast, whereas exon 20 insertions are capable of transforming cells, erlotinib and gefitinib are not effective on these *EGFR* mutants *in vitro* or in the clinic (11). As these results show, the clinical management of patients with *EGFR*-mutant tumors depends upon the nature of the mutation present and, therefore, requires accurate and comprehensive mutation detection strategies.

The research of He and colleagues, presented in their article in this issue of *Clinical Cancer Research*, represents the first effort to comprehensively characterize the frequency and sensitivity of exon 19 insertion mutations to *EGFR* TKIs. By retrospectively analyzing mutational data of non-small cell lung cancer, the authors identified 8 exon 19 insertions, representing 1% of all *EGFR* mutations. The authors also identified an additional 4 tumors from other centers. Like most *EGFR* mutations, exon 19 insertions are associated with adenocarcinoma histology and a null or limited smoking history. Of the 4 patients with metastatic disease, 3 responded to TKI, suggesting that *EGFR* exon 19 insertion mutations have a similar response rate to TKIs as exon 19 deletion mutations and the L858R, G719X, and L861Q point mutations. It remains unclear whether these mutations have the same progression-free and overall survival as the classic mutations.

Molecular modeling and crystallographic studies of *EGFR* have provided insight into the effect of different *EGFR* mutations on the structure of the tyrosine kinase domain. In particular, they have shed light on how the mutations may lead to constitutive activation of the kinase and affect sensitivity to TKIs. The tyrosine kinase domain of *EGFR* has 2 lobes: a smaller N-lobe and a larger C-lobe. The correct positioning of the C-helix (within the N-lobe) and the activation loop (within the C-lobe) are required for activation of the *EGFR* tyrosine kinase domain. In wild-type *EGFR*, ligand binding and receptor dimerization lead to the asymmetric interaction of the kinase domains of the 2 receptor dimers, leading to correct positioning of both the C-helix and the activation loop, thus favoring the active conformation of the kinase.

Authors' Affiliations: ¹Yale Cancer Center and ²Department of Pathology, Yale University School of Medicine, New Haven, Connecticut

Corresponding Author: Katerina Politi, Department of Pathology, Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, SHM-1234D, New Haven, CT 06510. Phone: 203-737-5921; Fax: 203-785-7531; E-mail: katerina.politi@yale.edu

doi: 10.1158/1078-0432.CCR-11-3282

©2012 American Association for Cancer Research.




Figure 1. The evolution of *EGFR* mutation testing. Direct sequencing of *EGFR* was initially used to detect mutations when they were first identified (2004, left). More recently, as sequencing technologies have evolved, genotyping assays are being used to screen for point mutations complemented by fragment length analyses to accurately detect insertion and deletion mutations in *EGFR* and other genes (2011, middle). Within the next 1 to 2 years, these technologies will be replaced by high-throughput sequencing of cancer-related genes, including *EGFR* (2012–2013, right), which will allow for the identification of all mutations in the gene using 1 assay. Right (2012–2013): green, *EGFR* gene; horizontal lines, sequencing reads that cover exonic regions of the gene; red squares, presence of a mutation in a read.

The L858 residue lies tucked in a hydrophobic pocket in the activation loop of the kinase when *EGFR* is in the inactive state. Substitution of leucine for arginine causes the activation loop to "flip out," destabilizing the inactive conformation and favoring the active conformation (12). Exon 19 deletion mutations occur in a protein strand (called the $\beta 3$ strand) adjacent to the C-helix. Although crystal structures of these mutants have been elusive, it is postulated that reducing the length of this strand may favor the active conformation of the kinase. Interestingly, a number of different exon 19 deletion mutations are observed in lung cancers, and the most common ones all lead to amino acid substitutions of residue L747. Similarly, the exon 19 insertion mutations all lead to substitution of residue L747. However, the exon 19 insertion mutations appear more uniform in length from these initial studies than do the exon 19 deletions, and they always lead to substitution of L747 to proline. It is possible that exon 19 insertions also alter the position

of the C-helix, favoring the active conformation of the kinase. Similarly, exon 20 insertion mutations, which occur at the beginning of the C-helix, also are likely to stabilize the active conformation of the kinase. Crystallographic studies of the exon 19 and 20 insertion and deletion mutations will be valuable to understand how these protein modifications affect sensitivity to TKIs.

The sensitivity of *EGFR* exon 19 insertions to TKIs, together with the low prevalence of these mutations in patients with lung adenocarcinomas, brings up the important issue of whether to incorporate routine testing for them (and other rare but "actionable" mutations) in the clinic. Currently, several institutions are pioneering the testing of all lung adenocarcinoma samples for known driver mutations, most of which are point mutations in genes such as *EGFR*, *KRAS*, *BRAF*, and *PIK3CA*. Compared with the identification of point mutations, detecting insertions and deletions is more complex. This is due to the fact that deletions and insertions can vary with respect to the size

and nature of the mutation, characteristics that are difficult to distinguish with many genotyping platforms. Fragment length analysis can overcome these problems and is a useful complementary test to genotyping analyses. Clinically, multiplatform analyses that combine these techniques are increasingly important as we gain more information on rare mutations and correlate specific mutations with response to different targeted therapies (Fig. 1). In the near future, these multiplatform analyses are likely to be replaced by targeted sequencing of cancer-related genes, using new-generation sequencing platforms and eventually whole-exome or whole-genome sequencing.

As molecular profiling of tumors enters mainstream practice, we will begin to identify a wider spectrum of mutations, some of which confer sensitivity to clinically available therapies or drugs in trials. One limitation of current *EGFR*-mutant lung cancer therapy is that the existing inhibitors have been tailored to inhibit the wild-type kinase. It is entirely possible that in the future we will have muta-

tion-specific inhibitors with differential activity based on the exact *EGFR* mutation identified. This exciting prospect of tailoring therapy to individual tumors poses challenges: Which assays should be used to ensure that all varieties of mutations are identified? How can we rapidly assess whether novel mutations are clinically significant and respond to specific drugs? Should we test for all mutations, even though their presence may be extremely rare? As He and colleagues' article elegantly presents, gathering information on rare mutations may be valuable for patient care.

Disclosure of Potential Conflicts of Interest

K. Politi licensed rights to a patent application for EGFR T790M mutation testing to Molecular MD. T.J. Lynch is on the board of directors for Infinity Pharma, is a consultant for Merck, and holds a patent with Partners Healthcare for an EGFR testing product.

Received January 20, 2012; accepted January 30, 2012; published OnlineFirst February 8, 2012.

References

1. He M, Capelletti M, Nafa K, Yun CH, Arcila M, Miller V, et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. *Clin Cancer Res* 2012;18:1790-7.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129-39.
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497-500.
4. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGFR receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004;101:13306-11.
5. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. *PLoS Med* 2005;2:e313.
6. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. *Nat Rev Cancer* 2010;10:760-74.
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947-57.
8. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121-8.
9. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005;2:e73.
10. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. *FEBS J* 2010;277:301-8.
11. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. *Lancet Oncol* 2011;13:e23-31.
12. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. *J Clin Oncol* 2008;26:1742-51.